Viatris logo

ViatrisNASDAQ: VTRS

Profile

Sector:

Healthcare

Country:

United States

IPO:

17 March 1980

Next earnings report:

28 February 2025

Last dividends:

23 August 2024

Next dividends:

22 November 2024
$15.21 B
-18%vs. 3y high
95%vs. sector
-vs. 3y high
-vs. sector
-15%vs. 3y high
36%vs. sector
-3%vs. 3y high
25%vs. sector

Price

after hours | Fri, 15 Nov 2024 23:52:41 GMT
$12.74+$0.22(+1.78%)
$3.75 B$3.62 B
$3.75 B$94.80 M

Analysts recommendations

Institutional Ownership

VTRS Latest News

Viatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript)
seekingalpha.com15 November 2024 Sentiment: NEUTRAL

Viatris Inc. (NASDAQ:VTRS) will be participating in the UBS Global Healthcare Conference on November 12, 2024, at 11:45 AM ET. The company's Chief Financial Officer, Doretta Mistras, will be present, along with Ashwani Verma from UBS, who specializes in small to mid-cap biotech and specialty pharmaceuticals. Welcome to everyone attending the conference.

Bargain Priced Viatris Reports Strong Q3 Earnings Results
seekingalpha.com08 November 2024 Sentiment: POSITIVE

Viatris has announced impressive earnings results for the third quarter at a bargain price.

Viatris Inc. (VTRS) Q3 2024 Earnings Call Transcript
seekingalpha.com07 November 2024 Sentiment: NEUTRAL

Viatris Inc. (NASDAQ:VTRS) will hold its Q3 2024 Earnings Conference Call on November 6, 2024, at 8:30 AM ET. The call will feature company leaders including CEO Scott Smith and CFO Doretta Mistras, along with analysts from various financial institutions. Participants will be in listen-only mode during the call.

Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance
zacks.com07 November 2024 Sentiment: POSITIVE

VTRS's earnings and sales for the third quarter exceeded expectations. Their new products are doing very well.

Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics
zacks.com04 November 2024 Sentiment: POSITIVE

In addition to Wall Street's predictions for Viatris' (VTRS) earnings, take a look at forecasts for some important metrics to better understand how the company performed in the quarter that ended in September 2024.

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference
prnewswire.com29 October 2024 Sentiment: POSITIVE

PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a worldwide healthcare firm, has announced its participation in two upcoming healthcare conferences. More information about the presentations is provided below: UBS Global Healthcare Conference Date: Tuesday, November 12, 2024 Time: 8:45 a.m.

Viatris Named to Forbes' World's Top Companies for Women 2024 List
prnewswire.com29 October 2024 Sentiment: POSITIVE

PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a worldwide healthcare firm, has been recognized on Forbes' 2024 list of the World's Top Companies for Women. This honor is given in partnership with Statista, a leading provider of statistics and industry rankings.

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
globenewswire.com16 October 2024 Sentiment: POSITIVE

Lexicon will get an initial payment of $25 million, along with the possibility of additional payments based on regulatory and commercial achievements.

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
prnewswire.com16 October 2024 Sentiment: POSITIVE

Viatris Inc. is expanding its innovative range of treatments for cardiovascular diseases by partnering with Lexicon Pharmaceuticals for the exclusive rights to sotagliflozin in markets outside the U.S. and Europe. This medication was approved by the U.S. FDA in May 2023 to help lower the risk of cardiovascular death and hospital visits related to heart failure in adults with certain health conditions. The agreement allows Viatris to utilize its global resources and expertise to explore more uses for sotagliflozin.

Viatris Announces the Pricing Terms of Maximum Tender Offer
prnewswire.com18 September 2024 Sentiment: POSITIVE

PITTSBURGH, Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has announced the pricing details for its cash tender offer, known as the "Maximum Tender Offer," made by its subsidiary Utah Acquisition Sub Inc. This offer is for up to a total of $575,003,000 of its outstanding 3.950% Senior Notes due in 2026, which must be validly submitted and not withdrawn by the Early Tender Date.

What type of business is Viatris?

Viatris Inc. is an American global pharmaceutical company formed as a result of the merger of Mylan and Upjohn on November 16, 2020. The company's headquarters is located in Canonsburg, Pennsylvania. The company manufactures and sells various types of medications: brand names (such as Viagra, Xanax, Lipitor), generics, including branded and complex generics, biosimilars, over-the-counter drugs, and active pharmaceutical ingredients. They cover a wide range of therapeutic areas such as cardiovascular, infectious diseases, oncology, immunology, CNS and anesthesia, women's health, diabetes and metabolism, gastroenterology, respiratory and allergy, dermatology.

What sector is Viatris in?

Viatris is in the Healthcare sector

What industry is Viatris in?

Viatris is in the Drug Manufacturers - Specialty & Generic industry

What country is Viatris from?

Viatris is headquartered in United States

When did Viatris go public?

Viatris initial public offering (IPO) was on 17 March 1980

What is Viatris website?

https://www.viatris.com

Is Viatris in the S&P 500?

Yes, Viatris is included in the S&P 500 index

Is Viatris in the NASDAQ 100?

No, Viatris is not included in the NASDAQ 100 index

Is Viatris in the Dow Jones?

No, Viatris is not included in the Dow Jones index

When was Viatris the previous earnings report?

No data

When does Viatris earnings report?

The next expected earnings date for Viatris is 28 February 2025